Design Therapeutics, Inc.

Historical 13F Holders

Symbol
DSGN
CUSIP
25056L103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 25056L103 since 12/18/2024, largest first.

Filer % of Class Filed
SR One Capital Fund I Aggregator LP 13D/A
10.7% 3/11/2026
Event 3/9/2026
Sirenia Capital Management LP 13G
9.5% 8/14/2026
Event 6/30/2026
Light Irrevocable Trust #1 dated April 22, 2019 13G/A
6.9% 2/7/2025
Event 12/31/2024
Star Irrevocable Trust #1 dated April 22, 2019 13G/A
6.9% 2/7/2025
Event 12/31/2024
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
Logos Global Management LP 13D/A
4.4% 11/18/2025
Event 11/14/2025
Point72 Asset Management, L.P. 13G/A
3.8% 8/14/2026
Event 6/30/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 2.26 k $28.4 k
2026 Q2 143 43.3 M $627 M
2026 Q1 126 38.0 M $404 M
2025 Q4 121 38.1 M $358 M
2025 Q3 98 36.0 M $271 M
2025 Q2 96 34.9 M $118 M
2025 Q1 101 34.5 M $133 M
2024 Q4 98 33.5 M $206 M
2024 Q3 105 32.1 M $172 M
2024 Q2 104 37.5 M $126 M
2024 Q1 99 31.7 M $128 M
2023 Q4 96 33.3 M $88.3 M
2023 Q3 94 32.9 M $77.7 M
2023 Q2 101 38.8 M $244 M
2023 Q1 103 38.7 M $223 M
2022 Q4 96 43.4 M $445 M
2022 Q3 88 41.4 M $693 M
2022 Q2 77 38.7 M $542 M
2022 Q1 65 38.0 M $615 M
2021 Q4 61 36.2 M $773 M
2021 Q3 53 28.3 M $415 M
2021 Q2 51 27.8 M $546 M
2021 Q1 44 25.8 M $755 M